Aptamer-Based Strategies to Boost Immunotherapy in TNBC

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Apr 13

PMID 37046670

Authors

Lisa Agnello

Annachiara dArgenio

Roberto Nilo

Monica Fedele

Simona Camorani

Laura Cerchia

Affiliations

Soon will be listed here.

Abstract

The immune system (IS) may play a crucial role in preventing tumor development and progression, leading, over the last years, to the development of effective cancer immunotherapies. Nevertheless, immune evasion, the capability of tumors to circumvent destructive host immunity, remains one of the main obstacles to overcome for maximizing treatment success. In this context, promising strategies aimed at reshaping the tumor immune microenvironment and promoting antitumor immunity are rapidly emerging. Triple-negative breast cancer (TNBC), an aggressive breast cancer subtype with poor outcomes, is highly immunogenic, suggesting immunotherapy is a viable strategy. As evidence of this, already, two immunotherapies have recently become the standard of care for patients with PD-L1 expressing tumors, which, however, represent a low percentage of patients, making more active immunotherapeutic approaches necessary. Aptamers are short, highly structured, single-stranded oligonucleotides that bind to their protein targets at high affinity and specificity. They are used for therapeutic purposes in the same way as monoclonal antibodies; thus, various aptamer-based strategies are being actively explored to stimulate the IS's response against cancer cells. The aim of this review is to discuss the potential of the recently reported aptamer-based approaches to boost the IS to fight TNBC.

Citing Articles

Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer.

Singh D, Haque S, Kim Y, Han I, Yadav D Front Immunol. 2024; 15:1455211.

PMID: 39720730 PMC: 11666570. DOI: 10.3389/fimmu.2024.1455211.

Integrated analysis reveals prognostic correlation and immune characteristics of a tumor-associated macrophage-based risk signature in triple-negative breast cancer.

Miao S, Bian C, Fang J, Wang S, You H, Zhou Y Transl Cancer Res. 2024; 13(10):5214-5232.

PMID: 39525038 PMC: 11543029. DOI: 10.21037/tcr-24-1037.

Nucleic acid-based drugs for patients with solid tumours.

Huayamares S, Loughrey D, Kim H, Dahlman J, Sorscher E Nat Rev Clin Oncol. 2024; 21(6):407-427.

PMID: 38589512 DOI: 10.1038/s41571-024-00883-1.

Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies.

Camorani S, Caliendo A, Morrone E, Agnello L, Martini M, Cantile M J Exp Clin Cancer Res. 2024; 43(1):92.

PMID: 38532439 PMC: 10964525. DOI: 10.1186/s13046-024-03014-x.

Recent Advancements of Aptamers in Cancer Therapy.

Venkatesan S, Chanda K, Balamurali M ACS Omega. 2023; 8(36):32231-32243.

PMID: 37720779 PMC: 10500573. DOI: 10.1021/acsomega.3c04345.

References

Ellington A, Szostak J . In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346(6287):818-22. DOI: 10.1038/346818a0. View

Agnello L, Tortorella S, dArgenio A, Carbone C, Camorani S, Locatelli E . Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors. J Exp Clin Cancer Res. 2021; 40(1):239. PMC: 8299618. DOI: 10.1186/s13046-021-02039-w. View

Adachi T, Nakamura Y . Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application. Molecules. 2019; 24(23). PMC: 6930564. DOI: 10.3390/molecules24234229. View

Li L, Xu S, Yan H, Li X, Safari Yazd H, Li X . Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives. Angew Chem Int Ed Engl. 2020; 60(5):2221-2231. DOI: 10.1002/anie.202003563. View

Du Y, Zhang D, Wang Y, Wu M, Zhang C, Zheng Y . A highly stable multifunctional aptamer for enhancing antitumor immunity against hepatocellular carcinoma by blocking dual immune checkpoints. Biomater Sci. 2021; 9(11):4159-4168. DOI: 10.1039/d0bm02210a. View

Zhang J, Li W, Qi Y, Wang G, Li L, Jin Z . PD-L1 Aptamer-Functionalized Metal-Organic Framework Nanoparticles for Robust Photo-Immunotherapy against Cancer with Enhanced Safety. Angew Chem Int Ed Engl. 2022; 62(5):e202214750. DOI: 10.1002/anie.202214750. View

Xiang D, Zheng C, Zhou S, Qiao S, Tran P, Pu C . Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors. Theranostics. 2015; 5(10):1083-97. PMC: 4508498. DOI: 10.7150/thno.11711. View

Ramesh A, Brouillard A, Kumar S, Nandi D, Kulkarni A . Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy. Biomaterials. 2019; 227:119559. PMC: 7238715. DOI: 10.1016/j.biomaterials.2019.119559. View

Blind M, Blank M . Aptamer Selection Technology and Recent Advances. Mol Ther Nucleic Acids. 2017; 4:e223. PMC: 4345306. DOI: 10.1038/mtna.2014.74. View

10.

Camorani S, Tortorella S, Agnello L, Spanu C, dArgenio A, Nilo R . Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells. Pharmaceutics. 2022; 14(10). PMC: 9609037. DOI: 10.3390/pharmaceutics14102225. View

11.

Camorani S, Hill B, Fontanella R, Greco A, Gramanzini M, Auletta L . Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer. Theranostics. 2017; 7(14):3595-3607. PMC: 5596446. DOI: 10.7150/thno.18974. View

12.

Zhu G, Chen X . Aptamer-based targeted therapy. Adv Drug Deliv Rev. 2018; 134:65-78. PMC: 6239901. DOI: 10.1016/j.addr.2018.08.005. View

13.

Chan K, Kinghorn A, Hollenstein M, Tanner J . Chemical Modifications for a Next Generation of Nucleic Acid Aptamers. Chembiochem. 2022; 23(15):e202200006. DOI: 10.1002/cbic.202200006. View

14.

Xiao X, Li H, Zhao L, Zhang Y, Liu Z . Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications. Biomed Pharmacother. 2021; 143:112232. DOI: 10.1016/j.biopha.2021.112232. View

15.

Agnello L, Camorani S, Fedele M, Cerchia L . Aptamers and antibodies: rivals or allies in cancer targeted therapy?. Explor Target Antitumor Ther. 2022; 2(1):107-121. PMC: 9400792. DOI: 10.37349/etat.2021.00035. View

16.

Chen Z, Zeng Z, Wan Q, Liu X, Qi J, Zu Y . Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells. Biomaterials. 2021; 280:121259. PMC: 8724397. DOI: 10.1016/j.biomaterials.2021.121259. View

17.

Ghaedrahmati F, Esmaeil N, Abbaspour M . Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Commun (Lond). 2022; 43(2):177-213. PMC: 9926962. DOI: 10.1002/cac2.12394. View

18.

Li T, Yao F, An Y, Li X, Duan J, Yang X . Novel Complex of PD-L1 Aptamer and Holliday Junction Enhances Antitumor Efficacy in Vivo. Molecules. 2021; 26(4). PMC: 7921949. DOI: 10.3390/molecules26041067. View

19.

Fatima S, Khare S . Benefits and challenges of antibody drug conjugates as novel form of chemotherapy. J Control Release. 2021; 341:555-565. DOI: 10.1016/j.jconrel.2021.12.013. View

20.

Chen Y, Gao P, Pan W, Shi M, Liu S, Li N . Polyvalent spherical aptamer engineered macrophages: X-ray-actuated phenotypic transformation for tumor immunotherapy. Chem Sci. 2021; 12(41):13817-13824. PMC: 8549783. DOI: 10.1039/d1sc03997k. View